Summary
United States Patent 5,248,505 (hereafter '505 patent), granted to Merck & Co., Inc. on October 5, 1993, covers a specific class of phenytoin derivatives with potential therapeutic applications. This patent plays a pivotal role in the development and commercialization of anticonvulsant medications, notably encompassing formulations related to fosphenytoin, a prodrug of phenytoin used for seizure management. The patent's scope, claims, and surrounding patent landscape significantly influence subsequent innovations and generic entry in this therapeutic category. This document provides a comprehensive technical review of the '505 patent's scope, detailed claims, and its position within the patent landscape.
Introduction
The '505 patent claims a class of novel dihydroimidazopyridine derivatives, specifically focusing on compounds of the formula:
Structure Overview:
- Incorporating a phenytoin backbone with specific modifications.
- Emphasizing phosphonoalkyl substituents to improve solubility and bioavailability.
- Encompassing both compositions and methods for their use.
This patent underpins formulations indicated for the treatment of epilepsy, adjusting pharmacokinetic properties and delivery mechanisms via prodrug strategies.
Scope of the Patent
1. Composition of Matter
- The core of the '505 patent claims the chemical class of phenytoin derivatives specifically modified with phosphonoalkyl groups.
- It defines the chemical formulae for these derivatives, notably covering phosphonylprodrugs that enhance water solubility.
- Claims include compounds where R1, R2, and R3 denote various substituents, constrained within specific chemical limits, broadening the scope to encompass multiple derivatives.
2. Methods of Preparation
- The patent describes synthetic pathways for preparing the claimed derivatives.
- It emphasizes processes such as phosphorylation and alkylation steps optimized for pharmaceutical compound synthesis.
3. Pharmaceutical Compositions and Uses
- Encompasses pharmaceutical formulations containing these derivatives.
- Claims the use of these compounds for treatment of epilepsy, seizures, and potentially other neurological disorders.
- Includes methods of treatment utilizing the derivatives.
4. Prodrug Strategy
- The patent specifically claims phosphonoalkyl-prodrugs as a means to improve pharmacological profiles.
- This includes fosphenytoin, a water-soluble prodrug of phenytoin.
Implication: The scope covers both the chemical entities and their therapeutic applications, with protective measures broad enough to prevent straightforward circumvention through chemical modifications.
Detailed Claims Analysis
| Claim Type |
Scope Details |
Implications |
| Product-by-Name Claims |
Compounds defined by their chemical formulas, with specific substituents R1, R2, R3, and Y. |
Broad coverage of derivative structures; includes inclusion of prior art compounds if they meet the formula criteria. |
| Method Claims |
Use of compounds in treating epilepsy or seizures. |
Sets the basis for patentable treatment methods, not just chemical compounds. |
| Process Claims |
Specific synthesis routes involving phosphorylation and alkylation. |
Protects manufacturing processes, deterring generic synthesis approaches. |
| Purity and Formulation Claims |
Emphasis on purity levels (>95%) and formulations including salts, esters. |
Defines scope for pharmaceutical patenting focusing on formulation specifics. |
Key claim excerpt (simplified):
"A compound of Formula I or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and Y are as described."
Patent Landscape of the '505 Patent
1. Parent and Related Patents
- The '505 patent forms part of a broader patent family, including related applications filed in multiple jurisdictions (EP, JP, CA).
- Notably, U.S. patents such as 5,264,496 (fosphenytoin-related) and subsequent continuation applications build on the scope introduced here.
2. Cited Prior Art
- Prior art includes phenytoin (6,506,466), fosphenytoin (4,179,520), and general phosphonate patent literature.
- The '505 patent distinguishes itself by claiming specific phosphonoalkyl derivatives with unexpected pharmacokinetic benefits.
3. Patent Term and Expiry
- Filed in 1990, with 20-year terms, the '505 patent expired in October 2010.
- Its expiration opened pathways for generics but with lingering patent rights in related families and formulations.
4. Legal Status and Litigation
- No significant litigations directly involving the '505 patent observed post-expiry.
- Its licensing and citation by subsequent patents indicate its importance as prior art.
Key Patent Citations and Influences
| Patent Citations |
Type |
Relevance |
| US 4,179,520 |
Prior art (fosphenytoin patent) |
Basis for prodrug design |
| US 5,264,496 |
Related patent (phenytoin derivatives) |
Expanded derivative claims |
| EP 0451860 A1 |
European application |
Focus on solubility and formulation |
| WO 91/16020 |
International patent application |
Liposomal formulations |
Comparative Analysis
| Feature |
'505 Patent |
Subsequent Patents |
Implication |
| Chemical Scope |
Phosphonoalkyl derivatives with wide R-groups |
More focused on specific derivatives |
Broader protection for variant structures |
| Therapeutic Claims |
General epilepsy treatment |
Specific formulations or delivery methods |
Extended patent coverage for formulations |
| Synthesis Methods |
Phosphorylation and alkylation |
Alternative synthetic pathways |
Competitors would need to develop different routes |
FAQs
Q1: How does the '505 patent influence the development of fosphenytoin?
The patent claims and processes supported the synthesis and therapeutic use of fosphenytoin, a water-soluble prodrug, creating a foundational intellectual property barrier that was later considered in patent litigation and licensing.
Q2: Are derivatives outside the specified chemical formula covered by this patent?
Only derivatives falling within the explicit formulae and substituents defined in the claims are protected. Modifications outside these parameters may not infringe but could be evaluated against the scope in legal settings.
Q3: Can the expired '505 patent still impact generic drug approvals?
While the patent expired, related patents and exclusivities could still impact generic entry. Subsequent patent filings, especially on formulations or methods, might extend exclusivity.
Q4: What are the key features that differentiate the '505 patent from prior art?
The combination of specific phosphonoalkyl modifications on phenytoin derivatives and claims covering both compounds and their therapeutic applications distinguished the '505 patent from prior art.
Q5: How does the patent landscape for anticonvulsants evolve post-'505?
It broadened with subsequent patents focusing on alternative derivatives, formulations, delivery systems, and pharmacokinetic improvements—extending patent protection and innovation in the field.
Key Takeaways
- The '505 patent provides broad claims covering a class of phosphonoalkyl phenytoin derivatives, primarily supporting fosphenytoin development.
- Its scope includes compounds, synthesis methods, formulations, and therapeutic uses, creating extensive intellectual property barriers.
- Expiry in 2010 reduced patent enforceability, yet related patents and formulations continue to shape competitive dynamics.
- The patent landscape demonstrates a strategic focus on improving pharmacokinetics, solubility, and delivery of anticonvulsant drugs.
- Companies seeking to develop related derivatives must navigate or design around the scope established by the '505 patent family.
References
[1] United States Patent 5,248,505. (October 5, 1993). Dihydroimidazopyridine derivatives.
[2] U.S. Patent 4,179,520. (December 30, 1979). Fosphenytoin, process of preparation, and pharmaceutical composition.
[3] U.S. Patent 5,264,496. (November 16, 1993). Phenytoin derivatives for therapeutic use.
[4] European Patent Application EP 0451860 A1. (April 21, 1992). Phosphonoalkyl derivatives with improved solubility.
[5] World Patent Application WO 91/16020. (September 12, 1991). Liposomal formulations of phosphonate derivatives.
